TrialClinical and translational science2018

Initial Clinical Experience of RP5063 Following Single Doses in Normal Healthy Volunteers and Multiple Doses in Patients with Stable Schizophrenia.

Marc Cantillon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.